First PSYCH Investor Summit Programming Announced: In Conversation with Christian Angermayer & Rick Doblin
How can successful for-profit psychedelics organisations and investors support the change-making work of non-profits? What is the role of each in an increasingly competitive business ecosystem, where are the friction points and what does the ideal relationship look like?
PSYCH is pleased to announce the first, highly anticipated discussion of the PSYCH Investor Summit: Research and Development, a conversation between atai Life Sciences’ founder, Christian Angermayer and Multidisciplinary Association for Psychedelic Studies (MAPS) founder, Rick Doblin.
Join us on 7 July for this can’t-miss event. In a US$100 billion industry set to disrupt modern healthcare, hear important insights on the critical path forward from these leaders on the frontlines.SECURE YOUR SEAT